Fisons assaults "undervalued" Rhone-Poulenc Rorer (RPR) bid:
This article was originally published in Clinica
Executive Summary
UK pharmaceutical company Fisons argues in its defence document countering a hostile bid that the Rhone-Poulenc Rorer offer undervalues the sales potential of its asthma medicine delivery devices. RPR's offer stands at 240 pence per share but could be increased by about 20 pence. Fisons' CEO Stuart Wallis says it would require a substantial increase in the offer to tempt Fisons to consider it seriously.